Abstract 4891
Background
Stereotactic body radiation therapy (SBRT) has been shown to have high efficacy to early-stage hepatocellular carcinoma (HCC) and is expected as an alternative to radiofrequency ablation (RFA). However, how liver function is impaired by SBRT, an important factor in the therapy for HCC, is uncertain. In this study, we compared the impact of SBRT on liver function and that of RFA.
Methods
We retrospectively analyzed 140 patients with single small (≤3 cm) hepatocellular carcinoma treated with SBRT or RFA between January 2014 and January 2019 in Kurashiki Central Hospital. A median age was 75 years, and 101 patients were male. Liver function was assessed by the albumin-bilirubin (ALBI) score before treatment (pre-ALBI) and 3 months after treatment (post-ALBI). Patients in the SBRT group were matched at a 1:1 ratio with patients treated with RFA by using propensity score method, and post-ALBI scores were compared between the two groups.
Results
Among the 140 patients, 42 and 98 patients were treated with SBRT and RFA, respectively. Before matching, patients in SBRT group were significantly older than patients in RFA group (78 vs. 72.5 years, p =.038), while patients’ sex, etiology of liver diseases, tumor size, tumor location and baseline liver function (both ALBI score and Child-Turcotte-Pugh score) were similar between the two groups. In SBRT group, median pre-ALBI and post-ALBI scores were -2.40 and -2.30, respectively, and the difference was not significant (p =.336). After propensity score matching, all the baseline characteristics were well balanced, and post-ALBI scores were not significant different between SBRT and RFA groups (-2.27 vs. -2.30, p =.828).
Conclusions
In our study, the impact of SBRT on liver function was comparable to that of RFA. Our findings help to promote SBRT as an expecting alternative treatment for early-stage HCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1058 - Assessment of CPS+EG, Neo-Bioscore and modified Neo-Bioscore in breast cancer patients treated with preoperative systemic therapy: a multicenter cohort study
Presenter: LING XU
Session: Poster Display session 2
Resources:
Abstract
1156 - The concordance of treatment decision guided by Oncotype and the PREDICT tool in early stage breast cancer
Presenter: Hadar Goldvaser
Session: Poster Display session 2
Resources:
Abstract
3447 - Influence of first treatment delay on survival among breast cancer subtypes
Presenter: Irene Zarcos Pedrinaci
Session: Poster Display session 2
Resources:
Abstract
3505 - Clinical features of early-stage (I-III) triple-negative breast cancer (TNBC) patients with tumors exhibiting low-overall change in molecular profile after neoadjuvant therapy.
Presenter: Nour Abuhadra
Session: Poster Display session 2
Resources:
Abstract
5442 - Meta-analysis in HER2+ early breast cancer therapies and cost-effectiveness in a Brazilian perspective
Presenter: Marcos Magalhaes
Session: Poster Display session 2
Resources:
Abstract
1570 - Anti-mullerian hormone (AMH) levels and antral follicle counts (AFC) may predict ovarian reserves before systemic chemotherapy (SC) in women with breast cancer(BC); a prospective clinical study
Presenter: Cetin Ordu
Session: Poster Display session 2
Resources:
Abstract
2698 - Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy.
Presenter: Giuseppe Cancello
Session: Poster Display session 2
Resources:
Abstract
3104 - Novel Blood Based Circulating Tumor Cell Biomarker For Breast Cancer Detection
Presenter: Chun-Yu Liu
Session: Poster Display session 2
Resources:
Abstract
4631 - Multi-Gene Prognostic Signatures and Prediction of Pathological Complete Response of ER-Positive HER2-Negative Breast Cancer Patients to Neo-Adjuvant Chemotherapy
Presenter: Claudia Mazo
Session: Poster Display session 2
Resources:
Abstract
4632 - Impact of menopause status on breast cancer outcomes and amenorrhea incidence during adjuvant tailored dose dense chemotherapy
Presenter: Andri Papakonstantinou
Session: Poster Display session 2
Resources:
Abstract